Masayuki Shimoda
Islet Cell Transplantation Project, Diabetes Research Center, Research Institute of National Center for Global Health and Medicine,
Tokyo
Japan
Research Article
Questionnaire Survey of Patients with Type-1 Diabetes Mellitus and their Family Members on the Acceptance of Newly Emerging Therapies
Author(s): Masayuki Shimoda and Shinichi MatsumotoMasayuki Shimoda and Shinichi Matsumoto
Objective: A current goal for the treatment of Type 1 Diabetes Mellitus (T1DM), an incurable disease, is to prevent deterioration of patients’ Quality Of Life (QOL) by maintaining excellent glycemic control. Health care providers expect that newly developed therapies will help improve QOL, but QOL must be assessed by the patients themselves. Therefore, it is critical to understand patients’ opinions about newly developed therapies. The aim of this study was to investigate patients’ opinions, especially their motivation to accept newly developed therapies.
Method: We analyzed questionnaires (n=85) completed by T1DM patients and family members about four newly developed therapies-Allogeneic Islet Transplantation (AIT), Islet Xenotransplantation (XIT), DNA vaccination, and Induced Pluripotent Stem cell therapy (IPS)-to investigat.. View More»
